Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).

Erin M BertinoRyan D GentzlerSarah CliffordJill M KolesarAlona MuzikanskyEric B HauraZofia PiotrowskaD Ross CamidgeThomas E StinchcombeChristie J LauJyoti MalhotraLiza C VillaruzCloud P PaweletzLynette ShollNaoko TakebeJeffrey A MoscowGeoffrey I ShapiroPasi A JänneGeoffrey R Oxnard

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Oral combination therapy with navitoclax and osimertinib was safe and feasible at RP2D with clinical efficacy. Early thrombocytopenia was common, supporting an target engagement by navitoclax. Further study of BCL-2/BCL-xL inhibition to enhance osimertinib activity is warranted.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
combination therapy
tyrosine kinase
stem cells
mesenchymal stem cells
bone marrow
replacement therapy